Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
News|Articles|January 2, 2026
FDA updates in urology: December 2025
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from December 2025.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! The year wrapped up with a flurry of regulatory approvals across prostate cancer, benign prostatic hyperplasia (BPH), and other benign conditions. Notable advances in December included clearance of the Hugo robotic system for urologic procedures as well as approvals for the ProVee and Zenflow Systems in BPH.
Related to this article
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
The completion of the first procedure marks the beginning of a controlled US commercial release.
Butterfly Medical has also submitted a premarket approval application to the FDA.
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Advertisement
Advertisement